ABBVIE INC.
ABBVAbbVie Inc. (ABBV) is a global biopharmaceutical company founded in 2013 as a spin-off from Abbott Laboratories. It specializes in the research, development, and marketing of innovative medicines across a range of therapeutic areas, including immunology, oncology, virology, and neuroscience. AbbVie is known for its flagship product, Humira, a leading treatment for autoimmune diseases. The company focuses on advancing scientific discoveries to deliver novel therapies and improve patient outcomes worldwide.
Dividend History
Investors can expect a dividend payout of $1.73 per share, scheduled to be distributed in 14 days on August 14, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| August 14, 2026 | $1.73 | 2026-07-15 | 2026-07-15 |
| May 15, 2026 | $1.73 | 2026-04-15 | 2026-04-15 |
| February 17, 2026 | $1.73 | 2026-01-16 | 2026-01-16 |
| November 14, 2025 | $1.64 | 2025-10-15 | 2025-10-15 |
| August 15, 2025 | $1.64 | 2025-07-15 | 2025-07-15 |
Dividends Summary
- Consistent Payer: ABBVIE INC. has rewarded shareholders with 55 dividend payments over the past 13 years.
- Total Returned Value: Investors who held ABBV shares during this period received a total of $57.42 per share in dividend income.
- Latest Payout: The most recent dividend of $1.73/share was paid 77 days ago, on May 15, 2026.
- Yield & Schedule: ABBV currently pays dividends quarterly with an annual yield of 2.72%.
- Dividend Growth: Since 2013, the dividend payout has grown by 332.5%, from $0.40 to $1.73.
- Dividend Reliability: ABBV has maintained or increased its dividend for 55 consecutive payments.
Company News
The Vanguard Health Care ETF (VHT) offers broad healthcare exposure with a low 0.09% expense ratio and 423 holdings, while the Invesco Biotechnology & Genome ETF (PBE) provides focused biotech exposure with 31 holdings and higher growth potential. PBE delivered a stronger 40.88% one-year return but experienced greater volatility with a 37.84% max...
Vanguard Health Care ETF (VHT) outperforms VanEck Biotech ETF (BBH) with lower fees (0.09% vs 0.35%), higher dividend yield (1.6% vs 0.5%), and superior 5-year returns ($1,278 vs $1,004 on $1,000 invested). VHT offers broad diversification across 411 healthcare holdings, while BBH provides concentrated biotech exposure with 25 stocks and higher v...
The State Street Health Care Select Sector SPDR ETF (XLV) and Fidelity MSCI Health Care Index ETF (FHLC) both offer low-cost healthcare exposure with identical 0.08% expense ratios. XLV focuses on 60 mega-cap healthcare stocks and has delivered stronger 5-year returns ($1,332 vs $1,276 on $1,000 invested), higher dividend yield (1.60% vs 1.30%), ...
The article compares two healthcare ETFs: VanEck Pharmaceutical ETF (PPH), which focuses exclusively on 25 pharmaceutical companies with higher returns but higher costs, and State Street Health Care Select Sector SPDR ETF (XLV), which offers broader diversification across 60 healthcare positions with lower fees. While XLV outperforms over 10 year...
AbbVie, a pharmaceutical company spun off from Abbott in 2013, maintains Dividend King status with an attractive 2.7% yield well above industry averages. Despite a high earnings payout ratio of 330%, the company's cash flow-based payout ratio of 60% indicates a sustainable dividend. AbbVie's strong portfolio includes blockbuster drugs like Botox ...
